🇺🇸 FDA
Patent

US 9532989

Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines

granted A61KA61K31/497A61K31/519

Quick answer

US patent 9532989 (Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/497, A61K31/519, A61K45/06, A61P